This Article Free Full Text Free Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Wamsley, H. L. Articles by Wronski, T. J. Search for Related Content PubMed PubMed Citation Articles by Wamsley, H. L. Articles by Wronski, T. J. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB CALCIUM COMPOUNDS CALCIUM, ELEMENTAL Social Bookmarking                   What's this?

Selected Extraskeletal Effects of Systemic Treatment with Basic Fibroblast Growth Factor in Ovariectomized Rats

¹ Departments of Pathobiology
² Physiological Sciences, College of Veterinary Medicine, University of Florida, Gainesville, Florida, USA

Correspondence: Address correspondence to: Heather L. Wamsley, University of Florida, College of Veterinary Medicine, Veterinary Medical Teaching Hospital, Clinical Pathology Service, 2015 SW 16th Av, Box 100103C, Gainesville, Florida 32610, USA; e-mail:wamsleyh{at}mail.vetmed.ufl.edu

Basic fibroblast growth factor (bFGF) is a pleiotropic mitogen with a potent bone-forming effect, rendering it a potential osteoporosis therapy. This study examined selected extraskeletal effects of bFGF in ovariectomized rats, a well-established model of human postmenopausal osteopenia, to more fully characterize side effects associated with bFGF treatment. Five-month-old, osteopenic, ovariectomized rats were injected subcutaneously with vehicle or bFGF (1 mg/kg) daily for 3 weeks. Hematologic and biochemical analyses were performed; and kidneys, livers, and proximal tibiae were examined histologically and histomorphometrically. bFGF administration resulted in anemia that was due to a shift toward granulocyte production in the bone marrow. Increased granulocyte production was also observed in the liver of bFGF-treated rats, which exhibited a markedly increased number and area of hematopoietic foci. bFGF administration also caused mild glomerular hypertrophy that was not attended by significant biochemical evidence of glomerular dysfunction. The bone anabolic effect of subcutaneous bFGF administration was confirmed in the proximal tibia, and was associated with a significant decrease in urine fractional excretion of calcium in bFGF-treated rats. Though bFGF strongly stimulates bone formation at osteopenic skeletal sites, its extraskeletal effects may restrict the long-term use of bFGF in its current form as an osteoporosis therapy.

Key Words: Basic fibroblast growth factor • fibroblast growth factor-2 • anemia • myeloid hyperplasia • granulocytic hyperplasia • extramedullary hematopoiesis • glomerular hypertrophy • systemic effects • rats • bone

Abbreviations: bFGF, basic fibroblast growth factor (fibroblast growth factor-2) • °C, Celsius • EP, prostaglandin E receptor • g, gram • h, hour • IQR, interquartile range • IV, intravenous • kg, kilogram • G:E, granulocytic-to-erythroid ratio • mg, milligram • OVX, ovariectomized • PGE2, prostaglandin E2 • SC, subcutaneous

Toxicologic Pathology, Vol. 33, No. 5, 577-583 (2005)
DOI: 10.1080/01926230500243060


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				L. Xiao, P. Liu, X. Li, T. Doetschman, J. D. Coffin, H. Drissi, and M. M. Hurley Exported 18-kDa Isoform of Fibroblast Growth Factor-2 Is a Critical Determinant of Bone Mass in Mice J. Biol. Chem., January 30, 2009; 284(5): 3170 - 3182. [Abstract] [Full Text] [PDF]